GlassScriptPhysician profile
Natalia Gutierrez
NPI 1538371935
$9,477.16
in general payments reported to CMS, 2019-2025
52 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,312 · 2020: $1,464 · 2021: $1,088 · 2022: $1,045 · 2023: $1,393 · 2024: $1,133 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,567.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,448.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,204.08 | 2019-2025 | |
| Amgen INC. | $809.70 | 2019-2025 | Evenity, Prolia, Repatha |
| Sanofi-Aventis U.S. LLC | $530.35 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.14 | 2019-2025 | Jardiance |
| Pfizer INC. | $418.73 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $416.37 | 2019-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $403.27 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $284.71 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $276.77 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $248.37 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $237.65 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $236.23 | 2019-2024 | Trintellix |
| Eisai INC. | $224.29 | 2020-2025 | |
| Lilly USA, LLC | $211.37 | 2019-2024 | Jardiance, Emgality, Zepbound |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalia Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.